Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BZQ4
UPID:
NMNA2_HUMAN
Alternative names:
Nicotinamide mononucleotide adenylyltransferase 2; Nicotinate-nucleotide adenylyltransferase 2
Alternative UPACC:
Q9BZQ4; O75067; Q5T1Q3; Q8WU99; Q96QW1
Background:
Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2, also known as Nicotinamide mononucleotide adenylyltransferase 2, plays a crucial role in axon maintenance by delaying Wallerian axon degeneration. It catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP, showcasing versatility by also utilizing nicotinic acid mononucleotide (NaMN) albeit with lower efficiency.
Therapeutic significance:
Understanding the role of Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2 could open doors to potential therapeutic strategies.